Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.01M | 21.92M | 20.77M | 19.87M | 18.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.05M | 64.55M | 59.78M | 57.35M | 51.43M |
| Operating Income | -70.05M | -64.55M | -59.78M | -57.35M | -51.43M |
| Income Before Tax | -63.31M | -57.44M | -52.90M | -50.86M | -45.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.31 | -57.44 | -52.90 | -50.86 | -45.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.31M | -57.44M | -52.90M | -50.86M | -45.42M |
| EBIT | -70.05M | -64.55M | -59.78M | -57.35M | -51.43M |
| EBITDA | -69.69M | -64.19M | -59.43M | -57.01M | -51.10M |
| EPS Basic | -1.35 | -1.34 | -1.44 | -1.63 | -1.73 |
| Normalized Basic EPS | -0.85 | -0.84 | -0.90 | -1.02 | -1.08 |
| EPS Diluted | -1.35 | -1.34 | -1.44 | -1.63 | -1.73 |
| Normalized Diluted EPS | -0.85 | -0.84 | -0.90 | -1.02 | -1.08 |
| Average Basic Shares Outstanding | 188.12M | 171.29M | 151.68M | 131.74M | 110.70M |
| Average Diluted Shares Outstanding | 188.12M | 171.29M | 151.68M | 131.74M | 110.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |